A combination of levetiracetam and tiapride for outpatient alcohol detoxification: A case series

Journal of Addiction Medicine

Volumn 5, Issue 2, 2011, Pages 153-156

  Müller, Christian A ^a   Schäfer, Martin ^b   Banas, Roman ^a   Heimann, Hannah M ^a   Volkmar, Katharina ^a   Förg, Anna ^a   Heinz, Andreas ^a   Hein, Jakob ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Alcohol dependence; Alcohol withdrawal syndrome; Levetiracetam; Outpatient alcohol detoxification; Tiapride

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETIRACETAM; GAMMA GLUTAMYLTRANSFERASE; TIAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; NOOTROPIC AGENT; PIRACETAM;

ADULT; AGED; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL WITHDRAWAL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BREATHING RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HALLUCINATION; HUMAN; MALE; ORIENTATION; OUTPATIENT; PULSE RATE; SEDATION; SIDE EFFECT; SWEATING; TREATMENT RESPONSE; TREMOR; VALIDITY; VERTIGO; ALCOHOLISM; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; AGED; ALCOHOLISM; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; OUTPATIENTS; PIRACETAM; SUBSTANCE WITHDRAWAL SYNDROME; TIAPRIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052176732     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181ec5f81     Document Type: Article

References (30)

1. Agricola R, Mazzarino M, Urani R, et al. Treatment of acute alcohol withdrawal syndrome with carbamazepine: A double-blind comparison with tiapride. J Int Med Res 1982;10:160-165. (Pubitemid 12124568)
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994.
3. Bender S, Scherbaum N, Soyka M, et al. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: A randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int J Neuropsychopharmacol 2007;10:653-660. (Pubitemid 47517515)
4. Bennett B, Lamberty Y, Bizot JC, et al. Levetiracetam prevents signs of alcohol withdrawal in mice. New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 21, 2003; San Francisco [abstract NR689]. 2003;2003:58.
5. Chabolla DR, Harnois DM, Meschia JF. Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc 2003;35:1480-1481. (Pubitemid 36765571)
6. Franz M, Dlabal H, Kunz S, et al. Treatment of alcohol withdrawal: Tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci 2001;251:185-192. (Pubitemid 32963496)
7. Fuks B, Gillard M, Michel P, et al. Localization and photoaffinity labeling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol 2003;478:11-19. (Pubitemid 38366069)
8. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006;536: 102-108.
9. Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: Pharmacological profile in animals. Eur J Pharmacol 1992;222: 193-203.
10. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003;348:1786-1795. (Pubitemid 36514710)
11. Krebs M, Leopold K, Richter C, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: An open-label pilot trial. J Clin Psychopharmacol 2006;26:347-349. (Pubitemid 43804637)
12. LaRoche SM, Helmers SL. The new antiepileptic drugs: Scientific review. JAMA 2004;291:605-614. (Pubitemid 38500315)
13. Lepola U, Kokko S, Nuutila J, et al. Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial. Int J Clin Pharmacol Res 1984;4:321-326. (Pubitemid 15192664)
14. Lucht M, Kuehn KU, Armbruster J, et al. Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: A controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol 2003;38:168-175. (Pubitemid 36372408)
15. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866. (Pubitemid 38869327)
16. Malcolm R, Myrick H, Brady KT, et al. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001;10(Suppl):16-23. (Pubitemid 32199528)
17. Margineanu DG, Klitgaard H. Levetiracetam has no significant gammaaminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur J Pharmacol 2003;466:255-261. (Pubitemid 36412088)
18. Mariani JJ, Levin FR. Pharmacotherapy for alcohol-related disorders: What clinicians should know. Harv Rev Psychiatry 2004;12:351-366. (Pubitemid 40144221)
19. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004;164:1405-1412. (Pubitemid 38937851)
20. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995;286:137-146.
21. Patsalos PN. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol Ther 2000;85:77-85. (Pubitemid 30069478)
22. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet2004;43:707-724.
23. Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 1996;16:49-57.
24. Peters DH, Faulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994;47:1010-1032. (Pubitemid 24170836)
25. Scatton B, Cohen C, Perrault G, et al. The preclinical pharmacologic profile of tiapride. Eur Psychiatry 2001;16(Suppl 1):29s-34s.
26. Soyka M, Morhart-Klute V, Horak M. A combination of carbamazepine/ tiapride in outpatient alcohol detoxification. Results from an open clinical study. Eur Arch Psychiatry Clin Neurosci 2002;252:197-200. (Pubitemid 36068380)
27. Soyka M, Schmidt F, Schmidt P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: Additional evidence. Pharmacopsychiatry 2006;39:30-34. (Pubitemid 43235448)
28. Stahl SM. Psychopharmacology of anticonvulsants: Levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry 2004;65:1162-1163.
29. Wetterling T, Kanitz RD, Besters B, et al. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol 1997;32:753-760. (Pubitemid 28006015)
30. WHO. Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Forschungskriterien. Dilling H, Mombour W, Schmidt MH, Schulte-Warkwort E, eds. Huber, Bern, 1994.